Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
On any given day, the show will cover at least 20 stocks determined by co-hosts Joel Elconin and Dennis Dick along with producer Spencer Israel.
The content for PreMarket Prep is primarily based on the after hours and premarket trading action. Although the hosts do not tell you exactly what to buy and sell, they can suggest what not to do.
The “Old” News: Over the last few weeks, it was speculated that Johnson & Johnson JNJ would get approval for a one-dose COVID-19 vaccine. In fact, last Thursday afternoon a Johnson & Johnson executive said he was confident the company will be able to meet their 2021 commitment to the European Union with 200 million doses.
However, the chatter about the forthcoming approval was somewhat undermined by a weak market and the issue declined last week from $162.98 to $158.56. Clue number 1 not to chase the issue higher on the headline.
Over the weekend, Johnson & Johnson secured emergency authorization for its vaccine. As expected, its single-shot vaccine candidate has been cleared as the third vaccine in the U.S. for emergency use, a day after it received the unanimous backing of an independent Food and Drug Administration expert panel.
Pajama Traders Way Overshoot On The Upside: Since the announcement came while the markets were closed, the first opportunity for price discovery was at 4 a.m. ET. Keep in mind that the markets at this time are less liquid and prices can be way of whack with reality.
In the case of Johnson & Johnson, the issue spiked from its closing price ($158.46) by nearly $7, when it peaked at $165 just after 4 a.m. ET. To put that move into perspective, the range for the issue for the entire month of February was just under $10. Clue number two not to chase the issue higher.
PreMarket Prep Take On Early Price Action: When the issue was being discussed on the show, it had retreated from the $165 high and was changing hands in the lower $161 handle. The author of this article discounted the price action from the premarket and was skeptical that the issue could even revisit Friday’s high ($162.41) during the regular session.
Price Action During The Regular Session: After a $2 higher open, the issue went just another few cents to $161.53, well shy of Friday’s high and reversed course. As of 2 p.m. ET, the ensuing decline has found support well above Friday’s close ($158.46) only reaching $159.31 and rebounded to the $160 area.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.